Byoung-Shik Shim

Byoung-Shik Shim

Auto-generated profile, based on publicly available information

Byoung-Shik Shim

G+flas Life Sciences, Seoul, Korea

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2019 in Clinical and Experimental Vaccine Research
Verified
Journal Article
Open access
BSByoung-Shik Shim
Byoung-Shik Shim
KHKee-Jong Hong
Kee-Jong Hong
PMPuna Maya Maharjan
Puna Maya Maharjan
SCSunghwa Choe
Sunghwa Choe
Vaccination is one of the most successful strategies to prevent diseases caused by pathogens. Although various expression systems including Escherichia coli, yeast, insect, and mammalian cells are currently used for producing many of vaccines, these conventional platforms have the limitation of post-translational modification, high cost, and expensive scalability. In this respect, the plant-based expression system has been considered as an attractive platform to produce recombinant vaccines due to fast, cost-effective and scalable production as well as safety. This review discusses the development of plant-derived vaccines and the current stage of plant-based expression system.

7 March 2018 in Journal of Immunology Research
Verified
Journal Article
Open access
PDF file
BSByoung-Shik Shim
Byoung-Shik Shim
ICIn Su Cheon
In Su Cheon
ELEugene Lee
Eugene Lee
SPSung-Moo Park
Sung-Moo Park
YCYoungjoo Choi
Youngjoo Choi
MSMan Ki Song
Man Ki Song
Potential use of cholera toxin (CT) as a mucosal vaccine adjuvant has been documented in a variety of animal models. However, native CT is highly toxic to be used as a mucosal adjuvant in humans. Here, we demonstrate a new approach to generate a mucosal adjuvant by replacing the B subunit of CT with HIV-1 Tat protein transduction domain (PTD), which efficiently delivers fusion proteins into the cell cytoplasm by unspecific binding to cell surface. We compared the adjuvanticity and toxicity of Tat PTD-CTA1-Tat PTD (TCTA1T) with those of CT. Our results indicate that intranasal (i.n.) delivery of ovalbumin (OVA) with TCTA1T significantly augments the OVA-specific systemic and mucosal antibody responses to levels comparable to those seen with CT adjuvant. Moreover,in vivocytotoxic T lymphocyte activity elicited by TCTA1T was significantly higher than that elicited by a mutant TCTA1T (TmCTA1T) lacking ADP-ribosyltransferase function. In addition, coadministration of influenza M2 protein with TCTA1T conferred near complete protection against lethal influenza virus challenge. Importantly, TCTA1T, in contrast to CT, did not induce serum IgG antibody responses to itself and was shown to be nontoxic. These results suggest that TCTA1T may be a safe and effective adjuvant when given by mucosal routes.